.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,807,828

« Back to Dashboard

Details for Patent: 5,807,828

Title: Platelet aggregation inhibitors
Abstract:Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds.
Inventor(s): Scarborough; Robert M. (Belmont, CA)
Assignee: COR Therapeutics, Inc. (South San Francisco, CA)
Filing Date:Jun 05, 1995
Application Number:08/461,035
Claims:1. A method to inhibit thrombus formation in animal subjects, which method comprises administering to a subject in need of such treatment an effective amount of a peptide selected from the group consisting of:

or pharmaceutical composition thereof.

2. A method for treating a patient suspected of having a platelet-associated ischemic syndrome comprising administrating to the patient a therapeutically effective dose of a peptide selected from the group consisting of:

or pharmaceutical composition thereof.

3. The method of claims 1 or 2, wherein said peptide is a cyclic peptide comprising a bond between (1) a terminal Mpr and a terminal Cys or (2) a terminal Mpr and a terminal Pen.

4. The method of claims 1 or 2, wherein said peptide is PAI 80 Mpr-P-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No: 1).

5. The method of claims 1 or 2, wherein said peptide is PAI 81 Mpr-G-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:2).

6. The method of claims 1 or 2, wherein said peptide is PAI 82 Mpr-A-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:3).

7. The method of claims 1 or 2, wherein said peptide is PAI 83 Mpr-Aib-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:4).

8. The method of claims 1 or 2, wherein said peptide is PAI 84 Mpr-(N-Me-Arg)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:5).

9. The method of claims 1 or 2, wherein said peptide is PAI 85 Mpr-(N-Me-Ser)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:6).

10. The method of claims 1 or 2, wherein said peptide is PAI 86 Mpr-(D-Ala)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:7).

11. The method of claims 1 or 2, wherein said peptide is PAI 87 Mpr-(.beta.-Ala)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:8).

12. The method of claims 1 or 2, wherein said peptide is PAI 88 Mpr-(N-Me-Leu)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:9).

13. The method of claims 1 or 2, wherein said peptide is PAI 89 Mpr-(N-Me-Ala)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:10).

14. The method of claims 1 or 2, wherein said peptide is PAI 90 Mpr-Sar-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:11).

15. The method of claims 1 or 2, wherein said peptide is PAI 91 Mpr-V-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:12).

16. The method of claims 1 or 2, wherein said peptide is PAI 92 Mpr-S-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No: 13).

17. The method of claims 1 or 2, wherein said peptide is PAI 93 Mpr-Har-G-D-W-P-A-C-NH.sub.2 (SEQ ID No: 14).

18. The method of claims 1 or 2, wherein said peptide is PAI 94 Mpr-Har-G-D-W-P-(N-Me-Ala)-C-NH.sub.2 (SEQ ID No:15).

19. The method of claims 1 or 2, wherein said peptide is PAI 95 Mpr-Har-G-D-W-P-G-C-NH.sub.2 (SEQ ID No:16).

20. The methods of claims 1 or 2, wherein said peptide is PAI 96 Mpr-Har-G-D-W-P-(D-Ala)-C-NH.sub.2 (SEQ ID No:17).

21. The method of claims 1 or 2, wherein said peptide is PAI 97 Mpr-Har-G-D-W-P-P-C-NH.sub.2 (SEQ ID No:18).

22. The method of claims 1 or 2, wherein said peptide is PAI 98 Mpr-Har-G-D-W-P-(Sar)-C-NH.sub.2 (SEQ ID No:19).

23. The method of claims 1 or 2, wherein said peptide is PAI 99 Mpr-Har-G-D-W-P-(Aib)-C-NH.sub.2 (SEQ ID No:20).

24. The method of claims 1 or 2, wherein said peptide is PAI 100 Mpr-A-(Har)-G-D-W-P-Pen-NH.sub.2 (SEQ ID No:21).

25. The method of claims 1 or 2, wherein said peptide is PAI 101 Mpr-A-K-G-D-W-P-Pen-NH.sub.2 (SEQ ID No:22).

26. The method of claims 1 or 2, wherein said peptide is PAI 102 Mpr-D-(Har)-G-D-W-P-Pen-NH.sub.2 (SEQ ID No:23).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc